| Literature DB >> 29630366 |
Balbina García-Reyes1, Lydia Witt2, Björn Jansen2, Ebru Karasu1, Tanja Gehring1, Johann Leban3, Doris Henne-Bruns1, Christian Pichlo4, Elena Brunstein4, Ulrich Baumann4, Fabian Wesseler5, Bernd Rathmer5, Dennis Schade5,6, Christian Peifer2, Uwe Knippschild1.
Abstract
Inhibitors of Wnt production (IWPs) are known antagonists of the Wnt pathway, targeting the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. Since IWPs show structural similarities to benzimidazole-based CK1 inhibitors, we hypothesized that IWPs could also inhibit CK1 isoforms. Molecular modeling revealed a plausible binding mode of IWP-2 in the ATP binding pocket of CK1δ which was confirmed by X-ray analysis. In vitro kinase assays demonstrated IWPs to be ATP-competitive inhibitors of wtCK1δ. IWPs also strongly inhibited the gatekeeper mutant M82FCK1δ. When profiled in a panel of 320 kinases, IWP-2 specifically inhibited CK1δ. IWP-2 and IWP-4 also inhibited the viability of various cancer cell lines. By a medicinal chemistry approach, we developed improved IWP-derived CK1 inhibitors. Our results suggest that the effects of IWPs are not limited to Porcn, but also might influence CK1δ/ε-related pathways.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29630366 DOI: 10.1021/acs.jmedchem.8b00095
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446